1
|
Schinke C, Weinhold N, Delgado-Calle J. Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy. Front Oncol 2023; 13:1157555. [PMID: 36895479 PMCID: PMC9990495 DOI: 10.3389/fonc.2023.1157555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 02/06/2023] [Indexed: 02/23/2023] Open
Affiliation(s)
- Carolina Schinke
- Department of Hematology-Oncology Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, United States
| | - Niels Weinhold
- Department of Hematology-Oncology Systems Medicine & Computational Biology, Heidelberg University, Heidelberg, Germany
| | - Jesus Delgado-Calle
- Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States
| |
Collapse
|
2
|
Moser-Katz T, Joseph NS, Dhodapkar MV, Lee KP, Boise LH. Game of Bones: How Myeloma Manipulates Its Microenvironment. Front Oncol 2021; 10:625199. [PMID: 33634031 PMCID: PMC7900622 DOI: 10.3389/fonc.2020.625199] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 12/22/2020] [Indexed: 12/13/2022] Open
Abstract
Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most common hematological cancer behind Non-Hodgkin’s Lymphoma. Malignant transformation of plasma cells imparts the ability to proliferate, causing harmful lesions in patients. In advanced stages myeloma cells become independent of their bone marrow microenvironment and form extramedullary disease. Plasma cells depend on a rich array of signals from neighboring cells within the bone marrow for survival which myeloma cells exploit for growth and proliferation. Recent evidence suggests, however, that both the myeloma cells and the microenvironment have undergone alterations as early as during precursor stages of the disease. There are no current therapies routinely used for treating myeloma in early stages, and while recent therapeutic efforts have improved patients’ median survival, most will eventually relapse. This is due to mutations in myeloma cells that not only allow them to utilize its bone marrow niche but also facilitate autocrine pro-survival signaling loops for further progression. This review will discuss the stages of myeloma cell progression and how myeloma cells progress within and outside of the bone marrow microenvironment.
Collapse
Affiliation(s)
- Tyler Moser-Katz
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States
| | - Nisha S Joseph
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States
| | - Madhav V Dhodapkar
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States
| | - Kelvin P Lee
- Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, United States
| | - Lawrence H Boise
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States
| |
Collapse
|
3
|
Botta C, Caruso N, Bossio S, Storino F, Console G, Martino M, Mendicino F, Lucia E, Morelli R, Correale P, Morabito F, Gentile M, Vigna E. Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report. Front Oncol 2020; 10:967. [PMID: 32626658 PMCID: PMC7314974 DOI: 10.3389/fonc.2020.00967] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Accepted: 05/15/2020] [Indexed: 11/13/2022] Open
Abstract
Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the CD8/CD4 lymphocytes ratio). Our report provides evidence of the efficacy of the third generation TKI inhibitor ponatinib in combination with DLI as second line therapy for Ph+ ALL relapsing after an allo-SCT.
Collapse
Affiliation(s)
- Cirino Botta
- Hematology Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Nadia Caruso
- Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Sabrina Bossio
- Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Francesca Storino
- Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Giuseppe Console
- Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, "Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
| | - Massimo Martino
- Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, "Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
| | - Francesco Mendicino
- Hematology Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Eugenio Lucia
- Hematology Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Rosellina Morelli
- Medicine Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Pierpaolo Correale
- Medical Oncology Unit, Department of Hemato-Oncology and Radiotherapy, "Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
| | - Fortunato Morabito
- Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy.,Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital, East Jerusalem, Israel
| | - Massimo Gentile
- Hematology Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| | - Ernesto Vigna
- Hematology Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Hematology and Oncology Department, "Annunziata" Hospital of Cosenza, Cosenza, Italy
| |
Collapse
|
4
|
Leblay N, Maity R, Hasan F, Neri P. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. Front Oncol 2020; 10:636. [PMID: 32432039 PMCID: PMC7214816 DOI: 10.3389/fonc.2020.00636] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Accepted: 04/06/2020] [Indexed: 12/16/2022] Open
Abstract
Immunotherapy has recently emerged as a promising treatment option for multiple myeloma (MM) patients. Profound immune dysfunction and evasion of immune surveillance are known to characterize MM evolution and disease progression. Along with genomic changes observed in malignant plasma cells, the bone marrow (BM) milieu creates a protective environment sustained by the complex interaction of BM stromal cells (BMSCs) and malignant cells that using bidirectional connections and cytokines released stimulate disease progression, drug resistance and enable immune escape. Local immune suppression and T-cell exhaustion are important mediating factors of clinical outcomes and responses to immune-based approaches. Thus, further characterization of the defects present in the immune system of MM patients is essential to develop novel therapies and to repurpose the existing ones. This review seeks to provide insights into the mechanisms that promote tumor escape, cause inadequate T-cell stimulation and impaired cytotoxicity in MM. Furthermore, it highlights current immunotherapies being used to restore adaptive T-cell immune responses in MM and describes strategies created to escape these multiple immune evasion mechanisms.
Collapse
Affiliation(s)
- Noémie Leblay
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
| | - Ranjan Maity
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
| | - Fajer Hasan
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
| | - Paola Neri
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
| |
Collapse
|